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Abstract
Background: Back pain is one of the most expensive health complaints. Comparing the economic aspects of back
pain interventions may therefore contribute to a more efficient use of available resources. This study reports on a
long-term cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) of two treatments as viewed from a societal
perspective: 1) exposure in vivo treatment (EXP), a recently developed cognitive behavioral treatment for patients with
chronic low back pain who have elevated pain-related fear and 2) the more commonly used graded activity (GA)
treatment.
Methods: Sixty-two patients with non-specific chronic low back pain received either EXP or GA. Primary data were
collected at four participating treatment centers in the Netherlands. Primary outcomes were self-reported disability (for
the CEA) and quality-adjusted life years (for the CUA). Program costs, health care utilization, patient and family costs,
and production losses were measured by analyzing therapy records and cost diaries. Data was gathered before, during,
and after treatment, and at 6 and 12 months after treatment. Non-parametric bootstrap analyses were used to quantify
the uncertainty concerning the cost-effectiveness ratio. In addition, cost-effectiveness planes and cost-effectiveness
acceptability curves were performed.
Results: EXP showed a tendency to reduce disability, increase quality adjusted life years and decrease costs compared
to GA. The incremental cost-effectiveness ratios of both the CEA and CUA are in favor of EXP.
Conclusions: Based on these results, implementing EXP for this group of patients seems to be the best decision.
Trial registration: ISRCTN88087718
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Background
Non-specific chronic low back pain (CLBP) is not only one
of the most common health problems in Western societies,
it also is one of the most expensive in terms of health care
costs and costs to society [1]. The economic consequences
of chronic pain are felt not only by the patient; other
parties, such as the family, social environment, health care
providers, and employers, are all directly or indirectly
affected by the consequences of CLBP. In the Netherlands,
the total costs of back and neck pain have been estimated
at 1–2 % of the gross national product [2, 3]. In recent de-
cades, ‘disorders of the musculoskeletal system’ and ‘symp-
toms and ill-defined conditions’, which include non-specific
CLBP, were among the top five most expensive disorders in
the Netherlands [4, 5]. These figures are comparable to
those from Australia, Canada, France, Germany, Japan,
Spain, the United Kingdom, and the United States [1]. Over-
all, costs arising from productivity loss account for more
than 50 % of the total costs associated with CLBP [6–9].
The most favorable treatment approach for non-specific
CLBP incorporates cognitive behavioral therapy (CBT)
techniques. Meta-analyses have concluded that CBT
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treatments have positive effects on pain, disability, and
mood, both post-treatment and at follow-up [10]. Theory-
based therapies are also vital to increase the benefits for
CLBP patients and decrease costs [11]. In recent years,
evidence has accumulated to show that catastrophic be-
liefs about pain, pain-related fear and associated avoidance
behaviors are instrumental in the development and main-
tenance of CLBP [12, 13]. In common CBT approaches,
such as graded activity, increasing activity levels is pro-
moted irrespective of the degree of fear. Fearful patients
may benefit from these interventions.
Exposure in vivo (EXP) is a treatment that was specially
developed to reduce excessive pain-related fear. By sys-
tematically exposing patients to painful movements and
activities that they have been avoiding, an opportunity is
created to correct their catastrophic misinterpretations of
the association between movements and harm. So far,
EXP treatment has proven to be effective in improving
functional disability by diminishing pain catastrophizing
and pain-related fear [14–17].
EXP treatment is different from the more standard
graded activity (GA) treatment [18]. Whereas GA focuses
on positively reinforcing healthy behaviors and activity
levels, EXP specifically targets the reduction of pain-
related fear. In a multicenter randomized controlled trial,
Leeuw et al. [19] reported that EXP was superior to GA
for reducing the perceived harmfulness of daily activities
in CLBP patients. The treatments did not differ signifi-
cantly for functional disability, though the difference
almost reached significance in favor of EXP.
Information on effectiveness alone is not enough to
draw definite conclusions about the implementation of ei-
ther intervention. For example, when the effectiveness of
interventions is equal or did not differ significantly, one
intervention could result in other benefits, such as
reduced health care costs, reduced patient and family
related costs, and/or reduced productivity losses. Since
resources are scarce, current health care decision-making
is necessarily evidence-based, requiring proof that the ef-
fects of new interventions are actually worth the extra cost
of the intervention. Additional information is therefore
needed about the incremental costs of EXP versus GA.
Given the wide societal impact of the economic conse-
quences, it can be expected that, in this group of patients,
EXP will lead to fewer health care costs, patient and
family-related costs, and indirect costs.
The aim of this study therefore was to examine the cost-
effectiveness (CEA) and the cost-utility (CUA) of EXP
compared to GA from a societal perspective, using CLBP
patients from the study conducted by Leeuw et al. [19].
We hypothesized that although the effectiveness of EXP
and GA treatment may differ only slightly or not at all,
there would be a difference in utilities and societal costs in
favor of EXP, thus recommending implementation of EXP.
Methods
Design and patients
In a randomized controlled multicenter trial conducted by
Leeuw et al. [19], 85 CLBP patients were randomly
assigned to EXP (42 patients) or GA (43 patients) treat-
ment. Patients either were referred by physicians at vari-
ous outpatient facilities and hospital departments in the
southern part of the Netherlands or responded to an ad-
vertisement in a local newspaper. Patients were included if
they were between the ages of 18 and 65 and if their lower
back pain had lasted for at least three months. Further-
more, patients had to be sufficiently disabled (Roland
Disability Score >3) and at least moderately fearful of
movement, injury or reinjury (Tampa Scale of Kinesiopho-
bia >33). Patients were excluded if they were illiterate,
pregnant, involved in any litigation concerning their ability
to work or disability income, or engaged in substance
abuse that could interfere with treatment. Patients with
specific medical disorders, cardiovascular diseases, or ser-
ious psychopathology were also excluded.
Ethics
The Medical Ethics Committee of Maastricht University
Medical Centre + approved the research protocol, as did
the institutional committees at the participating institu-
tions. Participation in the study was on the basis of
informed consent.
Randomization and design
Patients were randomized to either EXP or GA treatment
at one of the four participating treatment centers following
a predetermined and computer-generated randomization
schedule, pre-stratified by therapist team and the degree of
pain catastrophizing and disability. For disability and pain
catastrophizing, the median score of the data from a previ-
ous randomized controlled trial was used as the cut-off
[20]. Within each stratum, we used a randomized block de-
sign with a block size of two. The randomization schedule
was only accessible to the research assistant performing the
randomization and concealed for those involved in patient
recruitment. The randomization was also concealed for the
therapists until the time when treatment started. Since
there was one team for both treatments the therapists were
not blinded to the content of the treatments being
compared.
Treatment assignment was concealed from participants
until they arrived at their first intervention session. After
the second pre-treatment measurement, patients received
a sealed envelope from the research assistant containing a
sheet of colored paper indicating their treatment assign-
ment, which they opened together with the psychologist
during the intake.
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The data analysts (ML, MG, RdK) were blinded during
all the data analyses. Blinding (patient allocation) was
broken afterwards.
Interventions
Graded exposure in vivo
EXP aims improve functional ability by systematically re-
ducing pain-related fear. The assumption is that patients
have developed propositional knowledge about the asso-
ciation between movements and aversive outcomes, as a
result of which protective responses such as avoidance
and escape behavior occur [21]. During exposure to the
conditioned stimuli, patients may experience that they ac-
tually overestimated the threat, correct the catastrophic
expectations and learn to inhibit their avoidance response
[22, 23]. The program consisted of 16 one-hour sessions
and was provided according to a standardized protocol.
EXP treatment started by analyzing a patient’s cata-
strophic misinterpretations and using the Photograph
Series of Daily Activities (PHODA) to establish a personally
tailored, graded hierarchy of fear-eliciting activities [24].
This was followed by two educational sessions led by the
rehabilitation physician and the therapist mini-team (con-
sisting of a psychologist and a physical or occupational
therapist). During these sessions, they explained the treat-
ment rationale to the patient by integrating the individual
complaints and the patient’s characteristics in the fear-
avoidance model. They further explained that protective
behaviors may have been adaptive during the acute pain
episode, but that they paradoxically worsen the pain prob-
lem in the chronic phase. During the remaining sessions,
patients were gradually exposed to the fear-provoking activ-
ities and/or movements according to the fear hierarchy
established by means of PHODA. A more detailed descrip-
tion of EXP can be found elsewhere [17, 19].
Graded activity
GA was developed by Wilbert Fordyce in the early 1970s
and aims to improve functional ability by positively reinfor-
cing healthy behaviors and activity levels using operant
learning principles [25]. Here, the GA treatment consisted
of approximately 25 one-hour sessions provided according
to a standardized protocol. GA started with a one-session
psychological intake followed by two educational sessions
(led by the rehabilitation physician and the therapist mini-
team, respectively) in which the treatment rationale was ex-
plained, emphasizing the negative effects of inactivity and
the positive effects of physical activity on well-being. Indi-
vidual treatment goals and baseline activity level were then
identified. In the subsequent sessions, a time-contingent
treatment schedule was initiated in which the amount of
activity was gradually increased using an individualized
quota system [25]. In contrast to EXP, the psychologist’s
role in GA was limited to two sessions at which
participants’ family members were helped to positively
reinforce any progress made during the treatment. More
information about GA is available elsewhere [19, 26].
Data collection
Before treatment, data was gathered about gender, age,
education level, employment status, and pain duration.
Additionally, fear of movement/reinjury was assessed
using the Tampa Scale for Kinesiophobia (TSK: [27]).
Cost measures
To evaluate the economic consequences of treatment
from a societal perspective, we assessed the intervention
costs, other health care costs, patient and family costs,
and productivity losses. The intervention costs (GA =
€1,969.39 and EXP = €2,166.84) have been calculated on
the basis of the time that the rehabilitation physician,
psychologist, and physical/occupational therapist spent on
the therapy. Travel expenses to the intervention have been
calculated based on the mean distance multiplied by
standard cost prices [28]. Other health care costs concern
all other pain-related health care utilization, including
visits to the general practitioner, specialist care, alternative
health care, consultations with a physical or occupational
therapist, hospitalization, and prescribed or over-the-
counter medication. Patient and family costs include out-
of-pocket costs, such as costs for home care, informal
care, and additional expenses. Productivity losses have
been calculated based on days absent from work due to
back pain.
Patients maintained a monthly cost diary that was used
to measure all health care costs, patient and family costs,
and productivity losses [29]. The time horizon of the eco-
nomic evaluation was 15 months from the start of the
treatment to the last follow-up measurement. Each cost
diary was filled out two months before treatment (to study
baseline differences), during the three months of treat-
ment, and at months 1 and 2, 5 and 6, and 11 and 12 after
treatment. Patients were included in the economic ana-
lysis if cost diary information was available for at least
three months after treatment.
The total costs were estimated using a bottom-up ap-
proach, where information on each element of service
used was multiplied by an appropriate standardized unit
cost and added up to arrive at an overall total cost [30].
For the cost valuation, we used standardized cost prices
from the Dutch manual for cost analysis in health care
research [28]. Where no standardized cost prices were
available, real tariffs or costs were used. Costs of medica-
tion were calculated using guideline prices [31]. Add-
itional prescription charges for prescribed medication
were also taken into account. Where medication data
were varied, the lowest cost price for the specific medi-
cation was used. We calculated prices of informal care
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using standardized cost prices based on general hourly
wages. Additional expenses were determined using the
costs patients recorded in their cost diaries.
Productivity losses were calculated according to the Hu-
man Capital Approach, which estimates the value of the
potential production loss over an entire period of absen-
teeism. Finally, productivity costs were calculated by
multiplying the number of days of absence from work by
the cost per day. Another method to measure productivity
losses is the Friction Cost Method, which is based on the
assumption that an organization needs a certain time span
(friction period) to replace an absent worker with another
worker. The definitive number of days of work absence is
then limited to the duration of the friction period, which
has been determined to be 23 weeks in the Netherlands
[28]. To deal with the methodological uncertainty of
choosing the Human Capital Approach, productivity costs
were also estimated using the Friction Cost Method in a
sensitivity analysis. Costs were expressed in euros using
the 2014 price level; if necessary, prices were indexed
using rates from Statistics Netherlands.
Outcome measures
Functional disability was assessed using the Quebec Back
Pain Disability Scale (QBPDS) [32, 33]. Patients were
asked to rate their difficulty in performing 20 activities
commonly affected by back pain on a seven-point rating
scale ranging from 0 (no trouble) to 6 (unable to). Total
scores ranged between 0 and 100. The QBPDS has high
internal consistency, good test-retest reliability and suffi-
cient responsiveness and validity [34, 35].
Utilities were based on the Short Form-36 (SF-36). The
SF-36 is a reliable and valid instrument for measuring
health-related quality of life [36]. Utilities are values or
preferences that respondents assign to a particular health
state and are expressed overall on a scale from 0 to 1 [30].
The utilities used in this study were derived using an algo-
rithm of the SF-6D, which estimates utilities based on the
health-related quality of life scores from the SF-36 [37]. In
this procedure, respondents were initially asked to answer
questions on the eight subscales of the SF-36 (physical
functioning, social functioning, limitations in physical
functioning, limitations in emotional functioning, mental
health, bodily pain, vitality, general health). The derived
utilities at the four measurement points were used to
compute the quality-adjusted life year (QALY) score by
using the area under the curve method [38]. This means
that the utilities were multiplied by the time in that par-
ticular health state and then added up to calculate the
total number of QALYs.
Outcome measures were assessed twice at baseline (pre-
treatment 1 and pre-treatment 2 two weeks later), during
treatment, directly after termination of treatment (post-
treatment), and at 6 and 12 months after treatment.
Statistical analyses
The primary analyses were performed according to the
intention-to-treat principle, meaning that we used data
from all participants, regardless of whether they received
the intervention. The analysis included patients for whom
at least three months of post-baseline data were registered
in the diaries. The costs per patient were calculated by ex-
trapolating the observed costs of each patient to a 15-
month period (treatment period and follow-up). Since our
time horizon only just exceeded a period of one year, we
decided not to discount for these three months. Missing
data for outcomes were replaced by the last value carried
forward method.
To verify whether randomization resulted in equal treat-
ment groups, we tested the pre-treatment scores of the
QBPDS, utilities, QALYs, and pre-treatment costs through
independent T-testing or non-parametric bootstrapping.
Distribution normality was checked by investigating skew-
ness and kurtosis. Normally distributed variables were
tested using independent T-testing and non-normally
distributed variables were tested using non-parametric
bootstrapping (1,000 replications). The non-parametric
bootstrap method estimates sampling distribution by tak-
ing repeated samples with replacement from the original
participant data [39]. Despite the usual skewness in the
distribution of costs, arithmetic means are generally con-
sidered to be the most appropriate measure for describing
cost data [40].
Additionally, bootstrapping was used to explore sample
uncertainty (5,000 replications). These bootstrap simula-
tions were conducted to quantify uncertainty concerning
the incremental cost-effectiveness ratio (ICER), yielding
information about the joint distribution of cost and effect
differences between EXP and GA.
Treatment choice depends on the maximum amount of
money that society is prepared to pay for a gain in effect-
iveness, which is a ceiling ratio. Currently, the Dutch
Council for Public Health and Health Care recommends
that only treatments resulting in €80,000 per QALY or less
should be eligible for reimbursement in diseases with the
highest burden, down to €16,000 per QALY in case of the
lowest disease burden [41]. As there is much uncertainty
surrounding this ceiling ratio, the results of this study are
also presented in a cost-effectiveness acceptability curve
(CEAC). The CEAC represents the uncertainty concern-
ing the cost-effectiveness of EXP compared to GA treat-
ment by looking at a range of ceiling ratio values [42].
In addition, the sensitivity of the research was measured
using one-way sensitivity analysis, which explores how
changing the value of one parameter while leaving the
others unchanged impacts the results [30]. We used this
to analyze the treatments’ impacts on cost-effectiveness
when the Friction Costs Method is used instead of the
Human Capital Approach to calculate productivity costs.
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Statistical analyses were performed using SPSS statistical
software version 20. Bootstrapping simulations were run
in Microsoft Excel.
Results
Patients and comparability
After screening, 85 patients were included in the study: 42
were randomized to EXP treatment and 43 to GA treat-
ment. An extensive flowchart of patient data, including
withdrawals and reasons for dropout and non-response
before and during the intervention, has been published by
Leeuw et al. [19]. Overall reasons for non-response and
dropout were unrelated to the content of the treatment.
Sixty-two patients completed enough diary entries during
the months of treatment and follow-up to be included in
the economic analysis: 72.1 % in the GA group (31 out of
43 patients) and 73.8 % in the EXP group (31 out of 42 pa-
tients). Baseline characteristics (age, gender, education,
pain duration, disability, costs) of patients excluded from
the economic evaluation were not significantly different
from those of the 62 patients included (all p > .10; data not
presented).
There were no statistical differences between the GA
and EXP groups as regards demographic variables, back
pain complaints, education level, work status, or level of
fear of movement (all p > .10) at baseline. The mean age of
the 62 participants was 46.3 years (SD = 8.98); 50 % were
women, 37 % were employed, 24 % were on sick leave and
27 % received disability pension. They had an intermediate
(48.4 %) or low level of education (43.5 %). Their mean
level of pain-related fear was 42.1 (SD = 6.28). Participants
reported having pain for on average 11.9 years (SD =
10.22). There was also no difference in costs, utilities, or
disability before the start of the interventions (see
Table 1).
Outcomes
Table 2 shows the change in disability and utilities (from
the start of treatment through 15-month follow-up) and
QALYs gained during the follow-up period. Although
EXP patients showed a larger improvement on disability
and generic quality of life compared to GA patients, the
difference did not reach statistical significance (p > .30).
Resource use utilization and productivity loss
During the one-year follow-up, EXP patients utilized
fewer resources than GA patients, with the exception of
prescribed medication, hours of unpaid help and unpaid
work (see Table 3).
Costs
The costs of the GA and EXP treatments were calculated
by multiplying the number of sessions by the costs of the
treatment team involved and travel expenses to the ses-
sions. Although GA treatment involved more sessions (25
compared to 16), EXP treatment appeared to be more ex-
pensive due to the involvement of the psychologist in al-
most every session. Table 2 presents the mean health care
costs (including the intervention costs), patient and family
costs, and production losses of both interventions and the
95 % confidence intervals obtained by bootstrapping. All
cost comparisons (except for intervention costs) between
EXP and GA were in favor of EXP, which means that pa-
tients who received EXP treatment incurred fewer total
Table 1 Mean (SD) and differences in demographic characteristics, pain-related fear, outcome variables, and cost components at an
eight-week baseline period per treatment group
Mean (SD) Mean difference (95 % CI)
Variables GA (n = 31) EXP (n = 31) EXP versus GA
Age (years) 45.45 (8.42) 47.13 (9.58) −1.67 (-2.90 to 6.26)
Gender (% female) 50 % 50 %
Education (%) (-0.51 to 0.13)
Low 41.9 % 45.2 %
Intermediate 41.9 % 54.8 %
High 16.1 % 0 %
QBPDS (0-100)b 53.53 (12.79) 55.02 (11.41) 1.48 (-4.67 to 7.64)
Utility (0-1)b 0.60 (0.07) 0.58 (0.05) −0.02 (-0.06 to 0.01)
Health care costsa 68.56 (30.27) 65.78 (38.68) −3.00 (-94.00 to 99.00)
Patient and family costsa 332.44 (94.59) 367.74 (84.98) 35 (-224.00 to 268.00)
Productivity lossa 1,126.98 (355.07) 754.83 (255.86) −372 (-1,205.00 to 456.00)
Total costsa 1,529.32 (371.80) 1,204.73 (282.12) −325 (-1,301 to 586)
GA graded activity, EXP gradual exposure, QBPDS Quebec Back Pain Disability Score, QALYs quality-adjusted life years. Costs are in euros and per patient
aDifference in mean (95 % confidence interval) derived using bootstrapping (1,000 replications)
bDifference in mean (95 % confidence interval) derived using independent t-tests or chi-square tests
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costs in the post-treatment year compared to those who
received GA treatment.
Cost-effectiveness planes, CEACs and uncertainties
The EXP program resulted in a greater mean health bene-
fit (2.2 improvement on the QBPDS) achieved at a lower
mean total cost (€2,634 cost savings) compared to GA.
The cost-effectiveness plane for the QBPDS, representing
the 5,000 bootstrap replications, is shown in Fig. 1. The
dominance of EXP treatment (i.e., less disability at lower
cost) was shown in 56 % of the replications (i.e., 56 % of
bootstrapped cost-effect pairs were in the southeast quad-
rant). Of all bootstrapped likelihood replications, 8 % were
located in the northwest quadrant (indicating inferiority),
Table 2 Mean scores at 15-month follow-up for mean outcome variables and total costs (in euros) per patient per treatment group
Mean (SD) Mean difference (95 % CI)
GA (n = 31) EXP (n = 31) EXP versus GA
QBPDSb 40.42 (22.34) 38.19 (20.84) −2.23 (-13.20 to 8.75)
Utility (SF36)b 0.68 (0.14) 0.66 (0.14) −0.15 (-0.08 to 0.05)
QALYb 0.82 (0.12) 0.83 (0.13) 0.01 (-0.6 to 0.07)
Treatment costs 1,969.39 (0) 2,166.84 (0) 197.45
Health care costsa 1,841.72 (595.12) 1,011.67 (220.68) −830 (-2,209 to 247)
P & F costsa 5,347.25 (1229.70) 5,012.60 (1302.51) −335 (-3,708 to 3,320)
Productivity lossa 4,002.20 (1484.43) 2,502.57 (1055.98) −1,500 (-4,987 to 1,907)
Total costsa 13,477.71 (2450.28) 10,843.50 (1747.89) −2,643 (-8,535 to 3,058)
GA graded activity, EXP gradual exposure, QBPDS Quebec Back Pain Disability Score, QALYs quality-adjusted life year, P & F costs patient and family costs
aDifference in mean (95 % confidence interval) derived using bootstrapping (1,000 replications)
bDifference in mean (95 % confidence interval) derived using independent samples T-test
Table 3 Mean (SD) resource utilization per patient by treatment group
Type of utilization Mean (SD) Mean (SD)
GA (N = 31) EXP (N = 31) Mean difference (95 % CI)b
Number of contacts:
General practitioner 2.74 (4.67) 2.13 (3.49) −0.65 (-2.82 to 1.34)
Medical specialist 2.02 (3.25) 1.98 (2.84) −0.02 (-1.50 to 1.50)
Other health care providersa 29.44 (51.01) 17.39 (27.10) −12.44 (-32.53 to 5.87)
Alternative health care 2.58 (5.53) 1.94 (9.44) −0.63 (-3.71 to 3.63)
Prescriptions for medication:
Anxiolytics 0.24 (0.99) 0.69 (2.66) 0.46 (-0.40 to 1.53)
Antidepressants 0.16 (0.90) 0.32 (1.41) 0.13 (-0.40 to 0.73)
Opioids 1.29 (3.59) 0.65 (1.93) −0.70 (-2.26 to 0.57)
Other medication 0.81(3.38) 1.17 (4.99) 0.38 (-1.61 to 2.58)
Over-the-counter medication 0.23 (0.50) 0.29 (0.53) 0.06 (-1.96 to 3.25)
Hospitalization (in days) 0.48 (2.69) 0
Hours of help:
Home care 45.24 (176.96) 10.32 (40.00) −35.16 (-112.26 to 12.02)
Paid domestic work 5.16 (18.28) 10.32 (31.08) 3.43 (-7.26 to 17.07)
Unpaid help 168.23(348.08) 179.26 (321.13) 19.26 (-140.76 to 182.94)
Hours absent from:
Unpaid work 308.99 (416.81) 332.92 (442.99) 14.44 (-188.02 to 228.64)
Usual activity 49.72 (100.98) 37.89 (76.05) −12.08 (-58.31 to 31.26)
Paid work 291.69 (501.99) 191.39 (362.60) −104.81 (-324.84 to 103.69)
GA Graded activity, EXP Exposure in vivo
aPhysiotherapist, occupational therapist, manual therapist, Mensendieck therapist, Cesar therapist, psychologist, dietician, pedicurist, masseur, orthopedist, and
social worker
b95 % confidence intervals derived with independent samples T-test
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26 % in the southwest quadrant (indicating that GA is
cheaper but also results in less reduction of disability) and
10 % in the northeast quadrant (implying that EXP is
more expensive but also more effective).
Figure 1 also presents the CEAC of the cost-effectiveness
analysis based on the QBPDS. Given a €16,000 willingness
to pay for an additional improvement on the QBPDS, the
probability of EXP treatment being cost-effective is 67 %.
In addition, the ICER based on QALYs showed a greater
health benefit (0.01 additional QALYs) and lower mean
total cost (€2,643 cost savings) in favor of EXP treatment.
Uncertainty analyses (shown in Fig. 2) were calculated
using 5,000 bootstrap replications of the cost-utility ratio
for QALYs comparing EXP to GA treatment. In this plane,
the dominance of EXP was shown in 49 % of the replica-
tions. Only a small number (10 %) are located in the infer-
ior quadrant, indicating the superiority of EXP. Figure 2
also presents the CEAC of the cost-utility analysis based
on QALYs. Given a €16,000 willingness to pay for an add-
itional QALY, the probability of EXP treatment being
cost-effective is 81 %. When the maximum ceiling ratio of
€80,000 is used, the probability diminishes slightly, to
76 %. This small decrease indicates that the final decision
is rather insensitive to the ceiling ratio chosen.
In addition, one-way sensitivity analyses were performed
using the main assumptions of the Friction Cost Ap-
proach instead of the Human Capital Approach. This re-
duced the productivity costs and, as a consequence, the
Fig. 1 Cost-effectiveness plane and CEAC for QBPDS for EXP versus GA. EXP = exposure in vivo, GA = graded activity, CEAC = cost-effectiveness
acceptability curve, QBPDS = Quebec Back Pain Disability Scale
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total costs in both groups. Since only two patients (one in
each group) were absent for more than 23 weeks, the
reduction in costs was almost equal between the groups,
which does not change the conclusion reached using the
Human Capital Approach. Finally, since absenteeism
accounts for more than 50 % of the total cost, we boot-
strapped the ICERs of the CEA and the CUA once more,
now excluding productivity costs fully. This leads to a
decreased percentage dominant ICERS for the CEA and
the CUA, resp. 51 % and 46 %.
Discussion
This is the first economic evaluation study to compare the
use of EXP and GA to treat chronic low back pain. In line
with our hypothesis, economic analysis showed that EXP
might be the more optimal treatment for CLBP patients
with moderate to high fear of movement, injury or
reinjury compared to GA treatment. An uncertainty
analysis found that EXP is preferable to GA in terms of
costs and utilities; this finding is robust and insensitive to
the ceiling ratio chosen. EXP showed a tendency to
improve functioning and QALYs and reduce total health
care and productivity costs.
As the ultimate objective of an economic evaluation
study is to find the difference in cost-effectiveness (incre-
mental cost per effect/QALY), changes to the effects/
QALYs only are not interesting without also considering
the cost of bringing about such changes [43]. Both incre-
mental cost-effectiveness ratios resulted in more health
benefits (functioning and QALYs) and lower total costs for
Fig. 2 Cost-effectiveness plane and CEAC for QALYs for EXP versus GA. EXP = exposure in vivo, GA = graded activity, CEAC = cost-effectiveness
acceptability curve, QALYs = quality-adjusted life years
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EXP. In addition, bootstrap simulations exploring sample
uncertainties were also favorable for EXP. Depending on
the threshold range, the probability of EXP being cost-
effective compared to GA varies between 83 % (threshold
€16,000/QALY) to 76 % per QALY (threshold €80,000/
QALY). Thus, regardless of the threshold (which varied in
this study between €0 and €80,000) [27], the final choice
for EXP is rather robust and insensitive to the ceiling ratio
chosen. Nevertheless, the probability of EXP being cost-
effective is a bit less for functioning, varying between 81 %
and 67 %. Although this is still large, one should take into
account that this also means that 33 % of the patients
might not benefit from EXP.
Looking at the cost-effectiveness results in greater detail,
the cost per QALY (derived from the SF-6D utilities) were
more favorable for EXP than GA when compared to the
cost per self-reported disability. However, there were
improvements compared with baseline for both interven-
tions: the difference between baseline and follow-up
SF-6D scores exceeded the proposed minimal important
difference of 0.03 for this instrument [43, 44], which indi-
cates that this seemingly small difference can be regarded
as beneficial enough for patients and health care profes-
sionals. On the cost side, EXP treatment was more expen-
sive when only considering the costs during the
intervention. However, during the 12-month follow-up
after the intervention, all the other health care and prod-
uctivity costs were higher for the participants who com-
pleted the GA intervention, resulting in overall higher
societal costs for GA.
As in earlier studies that looked at patients with non-
specific chronic pain [7] or psychiatric problems [45], the
societal costs consisted mainly of patient and family costs
originating from out-of-pocket costs (e.g., for help needed
at home, informal care, and additional expenses). In line
with other studies looking at CLBP [6–9], this study
revealed that productivity losses make up a large share of
the societal costs. From an economic perspective, these
results again underline the importance of applying a
societal viewpoint and incorporating these costs in a cost-
effectiveness analysis of patients with chronic pain. In
addition, this supports the use of a bottom-up data source
(e.g., in-depth questionnaires or patient diaries) instead of
a top-down approach (e.g., using public or private health
insurer claims databases or hospital databases) [9].
In our study, the data from the cost diaries gave us
insight into the health care consumption of patients with
CLBP during the 15-month follow-up. The patients in this
study visited their general practitioners twice during this
period, which was almost similar to the number of visits
to an alternative care or medical specialist. By comparison,
members of the general Dutch population visit their
general practitioners 0.75 times and a medical specialist
0.4 times on average per year [46].
Visits to physical and occupational therapists were
reported most often. Patients in the GA group visited a
physical or occupational therapist almost twice as often
as patients in the EXP group (29 versus 17 visits), which
could be explained by the time-contingent treatment
schedule with predefined end goals in the GA treatment.
It is possible that GA patients were dissatisfied with
their outcomes and continued to work with a physical or
occupational therapist. Another possible explanation is
that GA patients catastrophized more about the negative
consequences of their pain and perceived harmfulness of
activities [19] compared to EXP patients, and that this
led to higher health care utilization.
Although not significantly different, the GA group re-
ported more hours of absence from work in the year after
the intervention than the EXP group did. We do not have
a full explanation for this difference. Some of the hours
could have been spent on physical/occupational therapist
care, which could have occurred during working hours.
The previously mentioned fear of pain and activities may
be another explanation for the absenteeism. Although the
productivity costs are a substantial part of the total cost, it
has a relatively small impact on the bootstrapped ICERs.
Unlike the difference in costs between GA and EXP
treatment (resulting in fewer societal costs for EXP), the
difference in effects was negligible. This is in line with the
earlier clinical study conducted by Leeuw et al. [19]. One
possible explanation for this could be that the differences
between the interventions were not as distinct as assumed.
Some elements of EXP treatment may have been included
in the GA interventions, such as fear-provoking activities
and reassurance that all the activities were safe and
allowed.
This study has some limitations. The cost-effectiveness
and cost-utility study results were based on a small
sample: only 62 respondents were included in the eco-
nomic evaluation, instead of the requisite 110. Like almost
all trial-based economic evaluations, this economic evalu-
ation is powered on the main outcome of the effectiveness
study. Though we accounted for sample uncertainty using
bootstrapping, dropout may have been an issue. However,
dropout was not related to the content of the treatment,
and baseline characteristics of the patients included in the
economic analyses did not differ from those excluded on
account of a lack of economic data. Overall, the response
rate was good, with 92 % completing the cost diaries. The
bootstrap analysis, which corrected for the sample uncer-
tainty, revealed that the study results are quite robust.
Still, we believe that a larger sample might have resulted
in significant results, and more certainty regarding costs
and monetary benefits, which could have affected the
result of the cost-effectiveness calculation.
Patient time was not included as a separate cost. Ac-
cording to the Dutch guideline, a patient’s time costs are
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equal to their productivity costs plus the impact of the
illness-related change in spare time activities on their
quality of life plus absenteeism. Spare time is not mone-
tized since this could lead to double counting as it is
included in the measurement of quality of life.
The generalizability of the results of economic evaluation
studies has been discussed, which is linked to factors that
can differ between places, such as the availability of health
care resources, clinical practice patterns, prices, collection
of resource use and cost data, and to study perspective and
factors related to an RCT [47]. Our study was conducted
alongside an RCT, which may have limited the
generalizability. However, several aspects were taken into
account to increase the transferability to other settings in
the Netherlands and beyond. First, a broad societal perspec-
tive was adopted. This means that the level of decision-
making is society as a whole. Second, the valuation of re-
source use data was based on the Dutch manual for cost
analysis in health care research, using standardized cost
prices [28]. Third, to enable other settings to apply their
own prices to the unit of resource use, prices and resource
use were documented separately. Fourth, the study was
conducted at four treatment centers, thus better reflecting
variation in health care provision. Fifth, and finally, health
state preference values were derived from the generic SF-
6D, which uses tariffs obtained from a community survey.
This tariff is used as an international standard to derive
utilities from the SF-36 [37]. The use of this generic out-
come measure enables policymakers to make comparisons
between different diseases.
Since this is the first economic evaluation study to com-
pare EXP to GA treatment for CLBP, there are however no
similar economic evaluation studies to allow comparison. A
recent systematic review that investigated the results of
cost-effectiveness studies of interdisciplinary rehabilitation
and cognitive behavioral therapy concluded that these in-
terventions were cost-effective for sub-acute and chronic
low back pain, regardless of the comparisons and perspec-
tives adopted [48]. Only one study has evaluated GA treat-
ment in a population of people with CLBP [49], which
revealed that a combination of GA treatment and problem-
solving is more cost-effective than a combination of GA
treatment with problem-solving and active physical treat-
ment. To our knowledge, EXP treatment has never before
been evaluated in an economic evaluation study.
Conclusions
In conclusion, clinicians and policymakers should con-
sider the use of EXP treatment for patients suffering from
chronic low back pain since it seems to be more cost-
effective than GA treatment. Nevertheless, since the study
was underpowered, the conclusion should be treated
carefully.
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